Agios Pharmaceuticals (NASDAQ:AGIO) experienced a significant boost on Tuesday, with shares climbing 14.9% to $42.95 as of 2:52 p.m. EDT. The surge added approximately $327 million to the company's implied market capitalization following news that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease. The agency granted Priority Review and set a Prescription Drug User Fee Act (PDUFA) target date of November 1, 2026.
The stock's rally pushed it above the average Wall Street price target of $39.33, as tracked by Google Finance, representing a 9.2% premium. Shares also traded 34.2% above RBC Capital's $32 target, which the firm recently raised from $28, according to TradingView via The Fly. Bank of America maintains a $46 price target, implying about 7.1% upside from current levels.
If approved, mitapivat would become the first oral pyruvate kinase activator available for sickle cell disease, addressing a significant unmet medical need. Sarah Gheuens, chief medical officer and head of R&D at Agios, emphasized that sickle cell disease represents a large, underserved patient population, noting the filing is supported by over 1,300 patient-years of clinical data across hemolytic anemias.
Agios shares significantly outperformed the broader biotech sector on the day. The stock topped the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 13.5 percentage points and the SPDR S&P Biotech ETF (NYSEARCA:XBI) by 13.3 percentage points. Trading volume was notably elevated, with approximately 2.03 million shares changing hands, roughly 1.8 times the average volume of 1.11 million shares.
The clinical data supporting the application comes from the RISE UP study, which showed that 40.6% of patients receiving mitapivat achieved the hemoglobin-response endpoint, compared to just 2.9% for placebo. However, the study did not meet statistical significance on the annualized sickle-cell pain crises endpoint, and there was no meaningful improvement in fatigue. Dr. Biree Andemariam of the University of Connecticut Health noted in June that patients urgently need new treatment options despite these mixed results.
Agios reported first-quarter mitapivat net revenue of $20.7 million, up sharply from $8.7 million in the same period last year. The company held $1.0 billion in cash, cash equivalents, and marketable securities as of March 31, while reporting a net loss of $99.1 million for the quarter. Bank of America analysts believe Agios can likely meet the $26.9 million consensus estimate for second-quarter revenue, with a focus on converting scripts into paid sales and monitoring reimbursement trends, according to TradingView's Stocktwits feed.
The stock currently sits 6.6% below its 52-week high of $45.99. Agios is scheduled to report its second-quarter earnings on July 30 at 8:00 a.m. ET, which will provide further insight into commercial performance and pipeline developments.
